S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.14%) $0.928
USD/NOK
(0.32%) $10.88
USD/GBP
(0.01%) $0.792
USD/RUB
(0.01%) $92.59

Realtime updates for BioXcel Therapeutics Inc [BTAI]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
66.67%
return 24.34%
SELL
33.33%
return 43.88%
Last Updated28 Mar 2024 @ 16:00

-2.08% $ 2.82

BUY 62565 min ago

@ $3.11

Issued: 14 Feb 2024 @ 13:43


Return: -9.32%


Previous signal: Feb 14 - 11:27


Previous signal: Sell


Return: 3.15 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology...

Stats
Today's Volume 335 900
Average Volume 1.58M
Market Cap 94.84M
EPS $0 ( 2024-03-12 )
Next earnings date ( $-0.750 ) 2024-05-13
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.460
ATR14 $0.00500 (0.18%)
Insider Trading
Date Person Action Amount type
2023-12-14 Yocca Frank Buy 521 Common Stock
2023-12-14 Yocca Frank Sell 521 Restricted Stock Units
2023-12-14 Mehta Vimal Buy 2 609 Common Stock
2023-12-14 Mehta Vimal Sell 2 609 Restricted Stock Units
2023-12-14 Rodriguez Javier Buy 521 Common Stock
INSIDER POWER
-11.07
Last 81 transactions
Buy: 351 248 | Sell: 440 033

Volume Correlation

Long: -0.05 (neutral)
Short: 1.00 (very strong)
Signal:(49.976) Expect same movement, but be aware

BioXcel Therapeutics Inc Correlation

10 Most Positive Correlations
AGNC0.927
NWL0.905
BOCH0.904
PRAX0.896
YQ0.896
SLVO0.894
GRFS0.893
SHYF0.891
CASS0.888
CLPS0.888
10 Most Negative Correlations
CRSA-0.937
LONE-0.906
PPBT-0.903
SNCR-0.902
TSLA-0.897
MVBF-0.882
TLMD-0.88
EPZM-0.878
RMRM-0.876
MTEK-0.876

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioXcel Therapeutics Inc Correlation - Currency/Commodity

The country flag 0.41
( neutral )
The country flag 0.31
( neutral )
The country flag 0.00
( neutral )
The country flag 0.32
( neutral )
The country flag 0.00
( neutral )
The country flag -0.29
( neutral )

BioXcel Therapeutics Inc Financials

Annual 2023
Revenue: $1.38M
Gross Profit: $-198 000 (-14.35 %)
EPS: $-6.15
Q4 2023
Revenue: $376 000
Gross Profit: $-416 000 (-110.64 %)
EPS: $-0.760
Q3 2023
Revenue: $341 000
Gross Profit: $-171 000 (-50.15 %)
EPS: $-1.720
Q2 2023
Revenue: $457 000
Gross Profit: $431 000 (94.31 %)
EPS: $-1.830

Financial Reports:

No articles found.

BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators